Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > REGULATORY
REGULATORY
- US FDA Warns against Risk of CDAD in Patients Taking PPIs
February 9, 2012
- Drug Discovery Support Organization Needed to Prevent “Decay” of Drug Industry: Mr Hachiyama
February 8, 2012
- Prime Minister Noda Asks Korosho to Study Simultaneous Revisions of Medical, Nursing Fees Every 3 Years
February 7, 2012
- Japan’s Cancer Registry System Lags Behind Other Developed Countries: Mr Umemura of DPJ
February 7, 2012
- Growing Concerns that Premium for New Drug Development May Violate Antimonopoly Act
February 6, 2012
- National, Rosai Hospitals to Enhance Relationship Aiming at Joint Purchasing in July
February 3, 2012
- MHLW to Strengthen Counterfeit Drug Control Creating Public-Private Council
February 3, 2012
- PAFSC's 2nd Committee on Drugs Recommends Approval for Kyowa Kirin's ATL Treatment
February 2, 2012
- Application Based on Data from Public Domain Recommended for Baktar, Flagyl: PAFSC Second Committee
February 2, 2012
- MHLW Presents Tougher Restrictions on Reimbursement of Vitamins
February 1, 2012
- DPJ’s PAL Subcommittee to Discuss Legal Handling of Drugs and Medical Devices
February 1, 2012
- CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
January 31, 2012
- PAFSC’s First Committee Recommends Designation of Pasireotide Pamoate as Orphan Drug
January 30, 2012
- JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
January 30, 2012
- PAFSC’s First Committee Recommends Approval for Zyprexa for Depression in Bipolar Disorders
January 30, 2012
- MHLW Grants Fast Track Review Status for Applications for Generic Brand Name Change
January 27, 2012
- MHLW Presents New 5-Year Plan to Promote Clinical Trials
January 27, 2012
- CSIMC Recommend Approval for Basic Proposal for FY2012 NHI Pricing; 0.86% Price Cut for Long-Listed Drugs, 0.33% for Generics
January 26, 2012
- NHI Price Reduction Method Changed for Aricept, Flolan
January 26, 2012
- Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness
January 26, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…